R
Replay
Reprogramming biology by writing and delivering big DNA
About Replay
Replay.bio is a cutting-edge biotechnology startup focused on developing advanced genomic products. The company specializes in creating synthetic gene libraries, which are collections of artificially synthesized genes. These libraries are used to design, write, and deliver large-scale DNA sequences. Replay.bio's technology allows for the rapid and cost-effective synthesis of genes, optimizing and rewriting gene sequences to improve their functionality.
Replay.bio operates in the genomic and biotechnology market, serving clients such as research institutions, pharmaceutical companies, and healthcare providers. The company’s products have a wide range of applications, including writing simple genomes (like viral and bacterial genomes), complex genomes (such as synthetic human chromosomes), and even entire synthetic genomes for plants, fungi, and mammals.
The business model of Replay.bio revolves around providing specialized genomic products and services. They generate revenue by selling their synthetic gene libraries and offering custom gene synthesis services. Additionally, they collaborate with other companies and research institutions to develop new genomic therapies. For instance, Replay.bio has partnered with Syena, an oncology-focused product company, and the University of Texas MD Anderson Cancer Center to create advanced cell therapies for cancer treatment. These therapies combine the safety and efficacy of Natural Killer (NK) cells with the targeting ability of T Cell Receptors (TCRs) to fight tumors.
Replay.bio makes money through direct sales of their genomic products, licensing their technologies, and forming strategic partnerships for co-development of new therapies. Their innovative approach and advanced technologies position them as a key player in the rapidly growing field of genomics and synthetic biology.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Employees
- 31
- Open positions
- None listed
- Dealroom signal
- 69.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Spinout, Sustainable Development Goals, Biotech and Pharma, Climate Tech, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITIONOther financing | Apr 2026 | $0 | — | LEO pharma | ↗ |
| GRANTOther financing | Nov 2022 | $1.6M | — | Bill & Melinda Gates Foundation | ↗ |
Growth signals
Latest recorded traffic for Replay is 2.1K monthly website visits, down 38.2% over the last three months. Replay's team declined 13.9% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Replay in the San Diego ecosystem
The Replay office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed8 investors entered at this stage
KKR
OMX Ventures
Axial
Lansdowne Partners
Artis Ventures
Salt
DeciBio
Bill & Melinda Gates Foundation
Other known investors2 additional known investors
LEO pharma
University of Pittsburgh
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Replay on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Replay’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








